Evidence map›Paper›PMID 32131139›Full record

ArticleTransfusion medicine (Oxford, England)2020

Parvovirus B19 infection in sickle cell disease: An analysis from the Centers for Disease Control haemoglobinopathy blood surveillance project.

Suvankar Majumdar, Christopher J Bean, Christine De Staercke, James Bost, Robert Nickel, Thomas Coates, Andrew Campbell, Alexis Thompson

Open access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Transfusion medicine (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Suvankar MajumdarChildren's National Medical Center, George Washington University School of Medicine & Health Sciences, Washington, DC.ORCID https://orcid.org/0000-0003-1471-738X
Christopher J BeanDivision of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.ORCID https://orcid.org/0000-0001-7433-9769
Christine De StaerckeDivision of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, Georgia.
James BostChildren's National Medical Center, George Washington University School of Medicine & Health Sciences, Washington, DC.
Robert NickelChildren's National Medical Center, George Washington University School of Medicine & Health Sciences, Washington, DC.
Thomas CoatesDivision of Hematology, Children's Hospital Los Angeles, Los Angeles, California.
Andrew CampbellChildren's National Medical Center, George Washington University School of Medicine & Health Sciences, Washington, DC.
Alexis ThompsonFeinberg School of Medicine, Northwestern University, Chicago, Illinois.
Children's National · USCenters for Disease Control and Prevention · USChildren's Hospital of Los Angeles · USNorthwestern University · US

Funding

BLOOD SAFETY SURVEILLANCE AMONG PERSONS WITH SICKLE CELL DISEASE IN MISSISSIPPIU50DD000879 · DD · UNIVERSITY OF MISSISSIPPI MED CTR · PI MAJUMDAR, SUVANKAR · 2012 to 2013
$291k
CDC HHSIntramural CDC HHS CC999999NCBDD CDC HHS U1U50DD000879NCBDD CDC HHS U50 DD000879
6 · The paper itself

Abstract

objectiveIn the multicentre Haemoglobinopathy Blood Surveillance Project, to evaluate the seroprevalence of parvovirus B19 and DNA viral load in sickle cell disease (SCD).

backgroundAlthough the epidemiology of parvovirus B19 seropositivity in SCD has been well documented, there are few studies that have assessed possible persistent parvovirus DNAemia and associated risk factors including blood transfusion.

methodsA qualitative analysis of parvovirus B19 serology using ELISA and quantitative parvovirus B19 DNA by RT-PCR was performed in patients with SCD.

resultsOf 322 patients, 113 (35%) were parvovirus IgG positive and 119 (37%) were IgM positive at enrolment. The prevalence of IgG positivity increased with age. 71/322 (22%) were parvovirus DNA positive at enrolment with a mean viral load of 15 227 ± 55 227 SD. (range 72-329 238 IU/mL). Patients who were positive for parvovirus B19 DNA received a significantly higher red blood cell transfusion volume in the prior year compared to patients who were negative (mean RBC volume = 8310 mL vs 5435 mL, respectively; P = .0073). Seventy-seven patients had follow-up testing approximately 1 year after enrolment and 11/28 (39%) patients had persistently positive IgM.

conclusionFurther studies are needed to better understand the natural history of parvovirus B19 infection in SCD especially in relation to RBC transfusion as a risk factor, as well as disease outcome and severity.

Indexed as

Anemia, Sickle CellAntibodies, ViralDNA, ViralErythema InfectiosumImmunoglobulin GImmunoglobulin MParvovirus B19, HumanAdolescentAdultCenters for Disease Control and Prevention, U.S.ChildChild, PreschoolFemaleHumansInfantInfant, NewbornAntibodies, ViralDNA, ViralImmunoglobulin GImmunoglobulin Mhemoglobinopathyparvovirus B19sickle

Identifiers

PMID32131139
PMCPMC7461246
OpenAlexW3010517883

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.